Jonnalagadda_2018_Cardiovasc.Drugs.Ther_32_311

Reference

Title : Effect of Anagliptin and Sitagliptin in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: What Is the Real REASON Behind It? -
Author(s) : Jonnalagadda VG , Char HP , Ankana PK
Ref : Cardiovasc Drugs Ther , 32 :311 , 2018
PubMedID: 29516206

Related information

Citations formats

Jonnalagadda VG, Char HP, Ankana PK (2018)
Effect of Anagliptin and Sitagliptin in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: What Is the Real REASON Behind It?
Cardiovasc Drugs Ther 32 :311

Jonnalagadda VG, Char HP, Ankana PK (2018)
Cardiovasc Drugs Ther 32 :311